Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.
Enhertu gets an early thumbs up from the FDA – now decisions are due for Epizyme’s tazemetostat and Novo Nordisk's Rybelsus and Ozempic.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.